Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · Genomic Data Mining for Drug Discovery

Genomic Data Mining and the Revival of Natural Product Drug Discovery

Genome sequencing has shown that most microorganisms carry considerably more biosynthetic gene clusters than they express under normal laboratory conditions. The bottleneck in natural product drug discovery has consequently shifted from the discovery of new organisms to the mining and interpretation of genomic data at scale.

Pubrica AcademyWritten by a bioinformatics research analyst Reviewed bya genomics data reviewer Published10 October 2026 Last checked10 October 2026 Reading time8 minutes Sources10 peer-reviewed

Natural product drug discovery is the search for medically useful compounds produced by living organisms, historically bacteria, fungi and plants, through the processes of biosynthesis. Pharmaceutical interest in this source declined during the 1990s and 2000s because traditional screening, in which organisms are grown and their products tested under standard laboratory conditions, repeatedly rediscovered the same small number of known compounds. Genome sequencing has revived the field by revealing that most microbial genomes contain many more biosynthetic gene clusters (BGCs), the stretches of DNA that encode the complete production pathway of a compound, than the organism visibly expresses in culture. The discovery problem has consequently shifted from finding new source organisms to mining, interpreting and activating the genomic data that those organisms already carry.

Learning objectives

  • The reasons genome sequencing revealed a much larger pool of candidate compounds than classical screening had identified
  • The definition of a biosynthetic gene cluster and the reasons most clusters remain silent under standard laboratory conditions
  • The data-driven strategies used to access this larger pool: genome mining, metagenomics and combinatorial biosynthesis

Common misconceptions

  • “Natural product drug discovery slowed down because nature had largely run out of new compounds to find.” Genome sequencing studies have repeatedly shown that individual bacterial strains, including strains studied for decades, carry many more biosynthetic gene clusters than the number of compounds ever observed from them in culture. The slowdown in the field reflected a bottleneck in screening and data interpretation rather than a shortage of underlying biosynthetic potential.

Biosynthetic potential revealed by genome sequencing

Whole-genome sequencing of well-studied, prolific producer bacteria such as Streptomyces species showed that each strain carries dozens of distinct biosynthetic gene clusters, far more than the number of compounds the strain had been observed to produce under standard laboratory culture conditions1. This finding, replicated across many sequenced genomes as sequencing costs fell during the 2000s and 2010s, redefined the central problem in the field. Rather than discovering new organisms, researchers required methods to read and interpret the biosynthetic instructions already present in genomes that had been held in culture collections for decades2. Genome mining, the computational search of DNA sequence data for signature genes associated with known classes of natural product biosynthesis (such as polyketide synthases and nonribosomal peptide synthetases), became the principal means of exploiting this gap, and specialised bioinformatics platforms such as antiSMASH were developed to automate the detection and annotation of candidate biosynthetic gene clusters across large genomic datasets3.

Silencing of most biosynthetic gene clusters

A biosynthetic gene cluster present in a genome does not necessarily yield a detectable compound, because many clusters are transcriptionally “silent” or weakly expressed under the specific nutrient, temperature and growth conditions of a standard laboratory culture2. Reviews of strategies for activating silent gene clusters describe several complementary approaches: systematic variation of growth conditions (the “OSMAC,” one strain many compounds, approach); genetic manipulation of the cluster’s own regulatory genes to induce expression; chemical or genetic perturbation of global regulators and epigenetic controls that influence gene expression more broadly; co-culture of the producer organism with other microorganisms to elicit ecological competition responses; and insertion of the cluster into a different, more genetically tractable host organism (heterologous expression), in which it can be studied and expressed under controlled conditions24. Each of these methods exists because genomic data alone identify the presence of a candidate cluster and its likely product class but do not cause the organism to produce the compound in the laboratory; closing that gap accounts for most of the effort in discovery programmes based on genome mining4.

Access to unculturable microorganisms through metagenomics

A separate and complementary data source is metagenomics, the direct sequencing of all DNA present in an environmental sample (soil, marine sediment or a host organism’s microbiome) without prior isolation and culture of individual organisms5. This is significant because the large majority of environmental microbial species have never been successfully grown in standard laboratory culture, so that classical screening, which requires a culturable organism, systematically fails to detect their biosynthetic potential5. Metagenomic approaches enable researchers to mine biosynthetic gene clusters directly from environmental DNA and, where a cluster of interest is identified, to clone and express it in a cultivable host organism in order to produce and test the compound, without the need to culture the original source organism56. This approach has already yielded new compound classes from previously inaccessible symbiotic and marine microbial communities, and its scale depends directly on the growing size and quality of public metagenomic sequence databases and of the bioinformatics tools used to search them6.

Engineering of new compounds from known genetic components

Beyond the discovery of compounds that occur in nature, genomic and synthetic biology tools have also enabled combinatorial biosynthesis, the deliberate recombination of biosynthetic genes or gene modules from different natural pathways to produce new, non-natural compound analogues that would be difficult or impossible to obtain by conventional chemical synthesis7. Because modular biosynthetic systems such as polyketide synthases are organised into discrete, interchangeable units with partially predictable functions, researchers can in principle substitute or rearrange these units to generate compound variants with altered structures and potentially altered biological activity, an approach that depends entirely on accurate genomic and structural data regarding the organisation of the underlying enzymes7. Reviews of the role of synthetic biology in natural product discovery describe this as one of the clearest instances in which improved genomic data and improved DNA assembly and genome-engineering tools have directly expanded what is chemically achievable, rather than merely accelerating the discovery of compounds already present in nature78.

Data interpretation as the principal current bottleneck

As sequencing costs continued to fall during the 2010s, the volume of available genomic and metagenomic data exceeded the field’s capacity for manual inspection, so that automated, standardised bioinformatics interpretation, rather than data generation, became the critical rate-limiting step3. The review by Smanski and colleagues of the role of synthetic biology in accessing natural chemical diversity characterises this explicitly as a problem of data science as much as of biology: the practical challenge is no longer whether a genome contains interesting biosynthetic machinery, since most do, but whether a research group has the computational tools and reference databases required to annotate, prioritise and act on that information correctly at the scale at which genomic sequencing now produces it9. This has moved the field towards standardised, shared bioinformatics infrastructure, such as antiSMASH and curated reference databases of known biosynthetic gene clusters, so that research groups do not each independently resolve the same annotation problem and so that cluster predictions can be compared consistently across datasets from different groups39. The practical consequence for a research team beginning a natural product discovery project is that the limiting investment increasingly lies in bioinformatics capacity and data management (curating genomic and metagenomic datasets, applying and interpreting genome-mining software correctly, and determining which of many computationally identified candidate clusters merit the laboratory effort of activation and compound isolation) rather than in access to novel source organisms, which the field treated for decades as the primary constraint9. The historical review of natural product discovery by Katz and Baltz traces this shift across several distinct eras, from classical top-down screening to the genomics-driven renaissance described here, and observes that each era was defined by a different bottleneck: classical screening was limited by which organisms could be cultured and which compounds a simple bioassay could detect, whereas the current genomics-driven era is limited by the field’s capacity to reduce an abundance of computationally predicted candidates to the small number that merit the laboratory time required to confirm and characterise an actual compound10. Identifying which bottleneck currently applies has practical implications for the allocation of a research programme’s resources: substantial investment in new strain collection or environmental sampling, the priority of the classical era, now yields comparatively less value than investment in the bioinformatics pipeline, database curation and cluster-prioritisation capacity that determine how much of the biosynthetic potential of an available genomic dataset is tested in the laboratory910. This reallocation of effort also changes the expertise that a discovery programme requires from the outset: alongside microbiologists and natural product chemists, computational biologists and data curators capable of running, validating and interpreting genome-mining pipelines at scale have become as central to the output of a modern programme as the laboratory capacity to grow organisms and purify compounds, a staffing and training implication that follows directly from the current location of the field’s bottleneck. Programmes that have made this adjustment, establishing dedicated bioinformatics capacity alongside their laboratory teams rather than treating data interpretation as an occasional, outsourced task, are generally better positioned to realise the biosynthetic potential revealed by genome sequencing, rather than accumulating sequenced genomes whose candidate clusters never progress beyond computational prediction.

Key points

Key points

Genome sequencing revealed that microorganisms possess considerably greater biosynthetic capacity than classical screening detected. The central challenge of the field has therefore shifted from the discovery of new organisms to the mining, interpretation and activation of available genomic data, including data from microorganisms that cannot be cultured.

Practical application

Practical application

  1. Genome mining should be treated as a first-pass filter rather than a definitive result. A detected biosynthetic gene cluster indicates biosynthetic potential; confirmation of an actual compound typically requires one or more cluster-activation strategies (altered culture conditions, regulator manipulation or heterologous expression).
  2. Metagenomic data should be considered when the source organism cannot be cultured. Where classical isolation has failed for an environment of interest, cloning and heterologous expression of metagenomically identified clusters can circumvent this barrier.
  3. Genomic annotation tools should be paired with experimental validation. Automated genome-mining platforms predict candidate compound classes computationally; their output should be treated as a hypothesis to be tested rather than as a confirmed discovery.

Frequently asked questions

A biosynthetic gene cluster (BGC) is a group of physically clustered genes that together encode the complete enzymatic pathway required to produce a specific natural product, such as an antibiotic or another secondary metabolite.

Many clusters are transcriptionally silent or weakly expressed under typical laboratory growth conditions; their activation generally requires altered growth conditions, manipulation of regulatory genes or expression of the cluster in a different host organism.

Genome mining is the computational analysis of DNA sequence data to identify genes and gene clusters associated with known classes of natural product biosynthesis, in order to identify candidate compounds for further investigation.

Metagenomics sequences all DNA present in an environmental sample directly, without prior culture of individual organisms, thereby providing access to the biosynthetic potential of microorganisms that cannot be grown in the laboratory.

It is used to recombine biosynthetic genes or modules from different pathways deliberately in order to generate new compound analogues, including structures that would be difficult to produce by conventional chemical synthesis.

References

  1. Zerikly M, Challis GL. Strategies for the Discovery of New Natural Products by Genome Mining. ChemBioChem. 2009;10(4):625-633. read 10 October 2026. View on ChemBioChem
  2. Rutledge PJ, Challis GL. Discovery of microbial natural products by activation of silent biosynthetic gene clusters. Nature Reviews Microbiology. 2015;13:509-523. read 10 October 2026. View on Nature Reviews Microbiology
  3. Blin K, Shaw S, Kloosterman AM, et al. antiSMASH 6.0: improving cluster detection and comparison capabilities. Nucleic Acids Research. 2021;49(W1):W29-W35. read 10 October 2026. View on Nucleic Acids Research
  4. Bachmann BO, Van Lanen SG, Baltz RH. Microbial genome mining for accelerated natural products discovery: is a renaissance in the making? Journal of Industrial Microbiology & Biotechnology. 2014;41(2):175-184. read 10 October 2026. View on Journal of Industrial Microbiology & Biotechnology
  5. Milshteyn A, Schneider JS, Brady SF. Mining the metabiome: identifying novel natural products from microbial communities. Chemistry & Biology. 2014;21(9):1211-1223. read 10 October 2026. View on Chemistry & Biology
  6. Charlop-Powers Z, Owen JG, Reddy BVB, Ternei MA, Brady SF. Chemical-biogeographic survey of secondary metabolism in soil. Proceedings of the National Academy of Sciences. 2014;111(10):3757-3762. read 10 October 2026. View on PNAS
  7. Weissman KJ. Polyketide synthases: from genes to molecules. Natural Product Reports. 2015;32(4):436-453. read 10 October 2026. View on Natural Product Reports
  8. Pickens LB, Tang Y, Chooi YH. Metabolic Engineering for the Production of Natural Products. Annual Review of Chemical and Biomolecular Engineering. 2011;2:211-236. read 10 October 2026. View on Annual Review of Chemical and Biomolecular Engineering
  9. Smanski MJ, Zhou H, Claesen J, Shen B, Fischbach MA, Voigt CA. Synthetic biology to access and expand nature's chemical diversity. Nature Reviews Microbiology. 2016;14:135-149. read 10 October 2026. View on Nature Reviews Microbiology
  10. Katz L, Baltz RH. Natural product discovery: past, present, and future. Journal of Industrial Microbiology & Biotechnology. 2016;43(2):155-176. read 10 October 2026. View on Journal of Industrial Microbiology & Biotechnology

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Genomic Data Mining and the Revival of Natural Product Drug Discovery. Pubrica. https://pubrica.com/academy/original-research-article/drug-development-using-natural-products-the-effects-of-the-genomics-era/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Genome-Mining Project Scoping Checklist

This checklist may be used when scoping a natural product discovery project driven by genomic data.

[ ] Identified target genomes or metagenomic datasets and confirmed sequence quality/coverage
[ ] Selected genome-mining tools appropriate to the target compound class
[ ] Flagged candidate biosynthetic gene clusters and checked for known-pathway matches
[ ] Planned a cluster-activation strategy (culture conditions, regulator manipulation, heterologous host) for silent clusters
[ ] Considered whether metagenomic or culture-independent methods are needed for the target environment
[ ] Planned experimental validation steps for any computationally predicted compound

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s data and bioinformatics support team assists research teams in structuring genome-mining workflows, interpreting biosynthetic gene cluster annotations and documenting methodology for publication.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Exploitation of the full biosynthetic potential of genomic datasets

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.